Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02895906 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
A Phase 1 study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02895906 is a Phase 1 study that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 2 participants.
The verdict
NCT02895906, a Phase 1 study, has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.
Interventions
- DRUG NFC-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2017-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02895906
The ClinicalTrials.gov registry entry for NCT02895906 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NFC-1 is the first listed.
NCT02895906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02895906 about?
NCT02895906 is a clinical study titled "Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions". This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.
What is the current status of trial NCT02895906?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-11-28. Estimated completion is 2017-04-20.
What interventions are being tested in trial NCT02895906?
The interventions under investigation include: NFC-1 (DRUG).
Who is sponsoring clinical trial NCT02895906?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.